A 2010 ACS Nano study bioimaged hyaluronic acid (HA)–quantum dot conjugates in cirrhotic mice and found that, whereas the conjugates cleared from healthy liver within about three days, they persisted in carbon-tetrachloride-cirrhotic liver for more than eight days and shifted toward hepatic stellate cells, motivating HA derivatives as target-specific, long-acting carriers for chronic liver disease. The study established feasibility only: it provided no mechanistic account of why fibrotic liver enhances uptake and prolongs retention, the ~22 mol% HA modification degree and particle parameters were used without disease-context optimization, and whether HA–drug conjugates would show therapeutic benefit was left to future work. The later literature shows that therapeutic translation has been substantially delivered preclinically (HA–interferon-α conjugates outperforming PEGylated interferon in hepatic antiviral-marker induction; HA–TRAIL and drug-loaded HA micelles with antifibrotic efficacy in rodent models), and that pieces of the mechanistic picture exist (CD44 upregulation on activated stellate cells, Stabilin-mediated sinusoidal-endothelial clearance, capillarization and extracellular-matrix barriers). However, no study quantitatively dissects the relative contributions of receptor expression, hyaluronidase activity, loss of sinusoidal fenestration, extracellular-matrix sequestration, or reduced clearance capacity, and no systematic disease-context design rules for HA carrier parameters exist. The open problem is therefore the quantitative mechanistic account of HA-nanocarrier retention in fibrotic liver and the design rules that follow from it.

Background

Chronic liver injury drives fibrosis and ultimately cirrhosis, a major cause of morbidity and mortality worldwide. Two cellular changes define the fibrotic liver. First, hepatic stellate cells (HSCs), the vitamin-A-storing cells in the space between sinusoids and hepatocytes, activate into proliferative, fibrogenic myofibroblasts that deposit extracellular matrix (ECM, the collagen-rich scaffold surrounding cells). Second, liver sinusoidal endothelial cells (LSECs), which line the liver's specialized capillaries and normally carry open transmembrane pores called fenestrae, undergo capillarization: the fenestrae close and a basement membrane forms. Hyaluronic acid (HA) is a linear polysaccharide component of the ECM; circulating HA is cleared mainly by LSEC scavenger receptors, in particular Stabilin-2 (also called HARE, the hyaluronic-acid receptor for endocytosis), while CD44, the principal cell-surface HA receptor, is low on quiescent liver cells but rises on activated HSCs and many tumor cells. Consistent with altered production and clearance, serum HA increases with cirrhosis severity.

In this setting, Kim and colleagues (ACS Nano, 2010) asked whether HA could act as a target-specific, long-acting drug-delivery carrier for chronic liver disease. They conjugated near-infrared-emitting quantum dots (QDots — brightly fluorescent, photostable semiconductor nanocrystals used as imaging labels) to adipic acid dihydrazide-modified HA (HA-ADH, about 22 mol% modification) by amide coupling, obtaining particles of roughly 42 nm hydrodynamic diameter with a mildly negative surface charge. In vitro, HSC-T6 stellate cells and HepG2 hepatoma cells internalized the conjugates more strongly than normal FL83B hepatocytes. After tail-vein injection into mice, the conjugates localized predominantly to liver in both healthy and carbon-tetrachloride (CCl4, a standard toxicant-induced cirrhosis model) animals — but cleared from healthy liver within about 3 days while remaining detectable in cirrhotic liver for more than 8 days. Immunofluorescence and flow cytometry of dissected livers localized the conjugate mainly to LSECs in both groups, with a marked cirrhosis-associated shift toward HSCs (from about 14% to 33% of HA-positive nonparenchymal cells, statistically significant). The record of this work notes the behavior is reminiscent of the enhanced permeation and retention (EPR) effect — the tendency of nanoscale particles to extravasate through abnormal vasculature and linger where drainage is poor, a concept imported from tumor nanomedicine. Three gaps follow from the study: the mechanistic basis of the enhanced uptake and slower clearance in cirrhosis was not established; the degree of HA chemical modification and the particle physicochemical parameters (balancing receptor recognition, targeting of activated HSC, systemic distribution, and clearance) were not optimized in the disease context — the roughly 22 mol% modification used was not derived from such an optimization; and therapeutic translation was left to future work, which the group itself delivered from 2011 onward with HA–interferon-α conjugates.

Later work (Yang et al., 2011; Park et al., 2011; Yang et al., 2015; Thomas et al., 2015) delivered therapeutic translation at the preclinical level: HA–interferon-α conjugates with days-long hepatic residence that outperform PEG-Intron at inducing the hepatic antiviral marker OAS1 in mice, TGF-β siRNA delivery to cirrhotic liver with reducible HA conjugates, HA–TRAIL with antifibrotic efficacy in fibrosis rats, and drug-loaded HA micelles with antifibrotic effects in rats and cirrhotic mice. The mechanistic picture advanced only in fragments: CD44 upregulation on activated HSCs was documented and exploited for targeting; Stabilin-1/-2 were established as the LSEC scavenger receptors whose loss impairs hepatic clearance and itself causes perisinusoidal fibrosis; and later nanomedicine work reframed sinusoidal capillarization and ECM deposition chiefly as delivery barriers that particles must actively overcome — in tension with a simple EPR-like reading of the 2010 retention observation. No later study quantitatively decomposes the mechanisms of HA-conjugate retention in cirrhotic liver, and no systematic disease-context optimization of HA carrier parameters exists.

Problem Statement

Determine, quantitatively and at the molecular and tissue level, why systemically administered HA-based conjugates and nanocarriers show enhanced hepatic uptake and markedly prolonged hepatic retention in fibrotic/cirrhotic liver compared with healthy liver — in the source observation, near-infrared HA–QDot conjugates of about 42 nm and mildly negative surface charge prepared from roughly 22 mol% modified HA persisted in CCl4-cirrhotic mouse liver for more than 8 days while clearing from healthy liver within about 3 days, with the HA-positive nonparenchymal cells shifting from predominantly sinusoidal endothelial cells toward hepatic stellate cells in cirrhosis. The mechanistic question is to determine the relative contributions of the candidate mechanisms — upregulated HA receptors (CD44 on activated hepatic stellate cells), altered hyaluronidase (the HA-degrading enzyme) activity, sinusoidal capillarization with loss of endothelial fenestration, sequestration by deposited extracellular matrix, and reduced hepatic scavenger clearance of circulating HA (loss of liver sinusoidal endothelial cell Stabilin-2 and related HA-scavenger-receptor activity) — to each of the source's two outcomes, the enhanced hepatic uptake and the prolonged hepatic retention of the conjugate, and which mechanism or combination dominates for each outcome at the source's cirrhosis endpoint relative to healthy liver, controlling for the alternative explanations that the readout is dominated by sequestration of unconjugated probe species by the reticuloendothelial system (the mononuclear phagocyte network, including liver macrophages, that clears particulates from the bloodstream) or by disease-altered tissue optics. These controls are methodological validity conditions arising from the QDot-fluorescence readout, which cannot distinguish conjugated from unconjugated probe species — a limitation of hydrophobic metal-containing QDot probes that the same group later explicitly recognized (Kim et al., Biomacromolecules 2015). Because the source reports only these observations, the mechanistic analysis is to be literature-based rather than dependent on new experimental data, decomposing the relative contributions with an explicit per-mechanism evidence base and testable predictions of the measurable quantities and expected effect directions. On this basis, establish systematic design rules for HA-based liver-targeting carriers — degree of HA chemical modification, HA molecular weight, particle size, and surface charge — that quantitatively balance HA-receptor recognition, targeting of activated hepatic stellate cells, systemic distribution, blood residence, and whole-body clearance specifically in fibrotic/cirrhotic (not healthy) liver, stating the trade-off used to balance these criteria, and propose, as an experimental design and analysis plan, an in-vivo validation design in animal fibrosis models consistent with the source's own in-vivo cirrhotic-mouse setting. The clinical pharmacokinetics, therapeutic efficacy, and safety of HA–drug conjugates such as HA–interferon-α are out of scope; the carriers' own biodistribution, blood residence, and clearance remain in scope and are among the design criteria above.

References

  1. Kim KS, Hur W, Park SJ, Hong SW, Choi JE, Goh EJ, Yoon SK, Hahn SK. Bioimaging for Targeted Delivery of Hyaluronic Acid Derivatives to the Livers in Cirrhotic Mice Using Quantum Dots. ACS Nano, 2010. DOI: 10.1021/nn100589y. https://doi.org/10.1021/nn100589y
  2. Yang JA, Park K, Jung H, Kim H, Hong SW, Yoon SK, Hahn SK. Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis C virus infection. Biomaterials, 2011. DOI: 10.1016/j.biomaterials.2011.07.088. https://doi.org/10.1016/j.biomaterials.2011.07.088
  3. Park K, Hong SW, Hur W, Lee MY, Yang JA, Kim SW, Yoon SK, Hahn SK. Target specific systemic delivery of TGF-β siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis. Biomaterials, 2011. DOI: 10.1016/j.biomaterials.2011.03.044. https://doi.org/10.1016/j.biomaterials.2011.03.044
  4. Lee MY, Yang JA, Jung HS, Beack S, Choi JE, Hur W, Koo H, Kim K, Yoon SK, Hahn SK. Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection. ACS Nano, 2012. DOI: 10.1021/nn302538y. https://doi.org/10.1021/nn302538y
  5. Kim KS, Kim S, Beack S, Yang JA, Yun SH, Hahn SK. In vivo real-time confocal microscopy for target-specific delivery of hyaluronic acid-quantum dot conjugates. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012. DOI: 10.1016/j.nano.2012.05.014. https://doi.org/10.1016/j.nano.2012.05.014
  6. Yang JA, Kong WH, Sung DK, Kim H, Kim TH, Lee KC, Hahn SK. Hyaluronic acid-tumor necrosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis. Acta Biomaterialia, 2015. DOI: 10.1016/j.actbio.2014.10.002. https://doi.org/10.1016/j.actbio.2014.10.002
  7. Thomas RG, Moon MJ, Kim JH, Lee JH, Jeong YY. Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model. PLoS One, 2015. DOI: 10.1371/journal.pone.0145512. https://doi.org/10.1371/journal.pone.0145512
  8. Kim KS, Hyun H, Yang JA, Lee MY, Kim H, Yun SH, Choi HS, Hahn SK. Bioimaging of Hyaluronate-Interferon α Conjugates Using a Non-Interfering Zwitterionic Fluorophore. Biomacromolecules, 2015. DOI: 10.1021/acs.biomac.5b00933. https://doi.org/10.1021/acs.biomac.5b00933
  9. Li W, Zhou C, Fu Y, Chen T, Liu X, Zhang Z, Gong T. Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats. Acta Pharmaceutica Sinica B, 2020. DOI: 10.1016/j.apsb.2019.07.003. https://doi.org/10.1016/j.apsb.2019.07.003
  10. Yoshizaki Y, Yamasaki M, Nagata T, Suzuki K, Yamada R, Kato T, Murase N, Kuzuya A, Asai A, Higuchi K, Kaji K, Yoshiji H, Ohya Y. Drug Delivery with Hyaluronic Acid-Coated Polymeric Micelles in Liver Fibrosis Therapy. ACS Biomaterials Science & Engineering, 2023. DOI: 10.1021/acsbiomaterials.3c00327. https://doi.org/10.1021/acsbiomaterials.3c00327
  11. Zhang LF, Wang XH, Zhang CL, Lee J, Duan BW, Xing L, Li L, Oh YK, Jiang HL. Sequential Nano-Penetrators of Capillarized Liver Sinusoids and Extracellular Matrix Barriers for Liver Fibrosis Therapy. ACS Nano, 2022. DOI: 10.1021/acsnano.2c03858. https://doi.org/10.1021/acsnano.2c03858
  12. Schledzewski K, Géraud C, Arnold B, Wang S, Gröne HJ, Kempf T, Wollert KC, Straub BK, Schirmacher P, Demory A, Schönhaber H, Gratchev A, Dietz L, Thierse HJ, Kzhyshkowska J, Goerdt S. Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. Journal of Clinical Investigation, 2011. DOI: 10.1172/jci44740. https://doi.org/10.1172/jci44740
  13. Gudowska M, Gruszewska E, Panasiuk A, Cylwik B, Flisiak R, Świderska M, Szmitkowski M, Chrostek L. Hyaluronic acid concentration in liver diseases. Clinical and Experimental Medicine, 2016. DOI: 10.1007/s10238-015-0388-8. https://doi.org/10.1007/s10238-015-0388-8
  14. Gibert-Ramos A, Andrés-Rozas M, Pastó R, Alfaro-Retamero P, Guixé-Muntet S, Gracia-Sancho J. Sinusoidal communication in chronic liver disease. Clinical and Molecular Hepatology, 2025. DOI: 10.3350/cmh.2024.0734. https://doi.org/10.3350/cmh.2024.0734
  15. Qhattal HS, Hye T, Alali A, Liu X. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano, 2014. DOI: 10.1021/nn405839n. https://doi.org/10.1021/nn405839n
  16. Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials, 2010. DOI: 10.1016/j.biomaterials.2009.09.030. https://doi.org/10.1016/j.biomaterials.2009.09.030
  17. Kim J, Park K, Hahn SK. Effect of hyaluronic acid molecular weight on the morphology of quantum dot-hyaluronic acid conjugates. International Journal of Biological Macromolecules, 2008. DOI: 10.1016/j.ijbiomac.2007.09.002. https://doi.org/10.1016/j.ijbiomac.2007.09.002
  18. Chen Z, Jain A, Liu H, Zhao Z, Cheng K. Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2019. DOI: 10.1124/jpet.118.256156. https://doi.org/10.1124/jpet.118.256156